Taylor M. Weis, PharmD, BCOP

Experts share final thoughts and advice for clinicians in the community to help optimize treatment success in CLL.

Emerging combination therapies and novel agents being studied as initial therapy for CLL are discussed.

Experts discuss factors and approaches to consider if choosing between a BTKi-based and BCL2i-based regimen for frontline therapy in CLL.

Kirollos S. Hanna, PharmD, BCPS, BCOP, discusses data on a BCL2 inhibitor in combination with anti-CD20 monoclonal antibodies in the treatment of CLL.

Taylor M. Weis, PharmD, BCOP, discusses data on a BTK inhibitor in combination with anti-CD20 monoclonal antibodies in the treatment of CLL.

Experts discuss the results of a head-to-head trial of ibrutinib versus acalabrutinib in CLL and the cardiovascular toxicity associated with BTK inhibitors.

Taylor M. Weis, PharmD, BCOP, discusses the role of pharmacists in toxicity prevention and management with BTK inhibitor therapy in CLL.

A review of long-term efficacy and safety data on the use of BTK inhibitor monotherapy in the frontline setting, plus insights from clinical practice.

Experts discuss triggers for initiating therapy in a patient with CLL, in addition to the goals of therapy.

Taylor M. Weis, PharmD, BCOP, discusses NCCN guidelines for first-line therapy as well as the rationale behind the rapid change in treatment concepts for CLL.

Kirollos S. Hanna, PharmD, BCPS, BCOP, provides an overview of the shifts in treatments, trends, and outcomes seen over the past decade in CLL.